JP2011503184A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503184A5
JP2011503184A5 JP2010534042A JP2010534042A JP2011503184A5 JP 2011503184 A5 JP2011503184 A5 JP 2011503184A5 JP 2010534042 A JP2010534042 A JP 2010534042A JP 2010534042 A JP2010534042 A JP 2010534042A JP 2011503184 A5 JP2011503184 A5 JP 2011503184A5
Authority
JP
Japan
Prior art keywords
morpholino
protected
ring nitrogen
group
subunit monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503184A (ja
JP5512533B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012804 external-priority patent/WO2009064471A1/en
Publication of JP2011503184A publication Critical patent/JP2011503184A/ja
Publication of JP2011503184A5 publication Critical patent/JP2011503184A5/ja
Application granted granted Critical
Publication of JP5512533B2 publication Critical patent/JP5512533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534042A 2007-11-15 2008-11-14 モルホリノオリゴマーの合成方法 Active JP5512533B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98820007P 2007-11-15 2007-11-15
US98819207P 2007-11-15 2007-11-15
US60/988,192 2007-11-15
US60/988,200 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014063314A Division JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法

Publications (3)

Publication Number Publication Date
JP2011503184A JP2011503184A (ja) 2011-01-27
JP2011503184A5 true JP2011503184A5 (enExample) 2012-01-12
JP5512533B2 JP5512533B2 (ja) 2014-06-04

Family

ID=40293764

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010534042A Active JP5512533B2 (ja) 2007-11-15 2008-11-14 モルホリノオリゴマーの合成方法
JP2014063314A Active JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法
JP2016129716A Pending JP2016196494A (ja) 2007-11-15 2016-06-30 モルホリノオリゴマーの合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014063314A Active JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法
JP2016129716A Pending JP2016196494A (ja) 2007-11-15 2016-06-30 モルホリノオリゴマーの合成方法

Country Status (13)

Country Link
EP (1) EP2207779B1 (enExample)
JP (3) JP5512533B2 (enExample)
KR (1) KR101617472B1 (enExample)
CN (1) CN101861318A (enExample)
BR (1) BR122019021332A8 (enExample)
CA (2) CA2704261C (enExample)
DK (1) DK2207779T3 (enExample)
ES (1) ES2479393T3 (enExample)
HR (1) HRP20140646T1 (enExample)
IL (1) IL205776A0 (enExample)
MX (1) MX2010004955A (enExample)
RU (1) RU2606627C2 (enExample)
WO (1) WO2009064471A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
JP5991922B2 (ja) 2009-11-13 2016-09-14 サレプタ セラピューティクス， インコーポレイテッド アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
KR102182663B1 (ko) 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
DK2623507T3 (da) * 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
EP2638161A1 (en) 2010-11-12 2013-09-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
IL273838B (en) 2011-05-05 2022-09-01 Sarepta Therapeutics Inc Peptide and oligonucleotide conjugates, preparations containing them and their uses
EP2732035A2 (en) 2011-07-15 2014-05-21 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
WO2013082548A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
WO2013086441A2 (en) 2011-12-08 2013-06-13 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA3132111A1 (en) * 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
JP6542662B2 (ja) 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド オリゴヌクレオチドアナログのボロン酸結合体
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
EP3015467B1 (en) * 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
KR102275504B1 (ko) 2013-09-05 2021-07-09 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
EP3868772A1 (en) 2013-09-30 2021-08-25 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
RU2730681C2 (ru) 2014-03-12 2020-08-24 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
AU2015277924B2 (en) 2014-06-17 2021-02-25 National Center Of Neurology And Psychiatry Antisense nucleic acids
JP6673211B2 (ja) * 2014-10-14 2020-03-25 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CN114681621B (zh) 2015-05-19 2024-08-06 萨勒普塔医疗公司 肽寡核苷酸缀合物
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN108350005B (zh) * 2015-08-05 2024-02-06 卫材R&D管理有限公司 用于制备均一低聚物的手性试剂
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
HRP20201125T1 (hr) 2015-09-15 2020-10-30 Nippon Shinyaku Co., Ltd. Antisens nukleinska kiselina
WO2017047741A1 (ja) 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
JP2018538302A (ja) 2015-12-15 2018-12-27 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチド複合体
JP7393121B2 (ja) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー アンチセンス抗菌化合物および方法
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MY200252A (en) 2016-04-18 2023-12-16 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2017190041A1 (en) 2016-04-29 2017-11-02 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA3024178A1 (en) 2016-05-24 2017-12-14 Sarepta Therapeutics, Inc. Pharmaceutical composition comprising eteplirsen
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
CN109152792B (zh) 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
WO2018057430A1 (en) * 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
EP3554552B1 (en) 2016-12-19 2022-08-17 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
CN117298290A (zh) 2016-12-19 2023-12-29 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA49986A (fr) 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
KR102898787B1 (ko) 2018-05-10 2025-12-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
BR112020026542A2 (pt) 2018-06-26 2021-04-06 Nippon Shinyaku Co., Ltd. Composição que compreende oligonucleotídeo antissenso e uso da mesma para tratamento de distrofia muscular de duchenne
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
IL321667A (en) 2018-12-13 2025-08-01 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
JP7689078B2 (ja) 2019-11-13 2025-06-05 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4059943A4 (en) 2019-11-13 2024-01-31 Nippon Shinyaku Co., Ltd. METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND
EP4079329A4 (en) 2019-12-19 2024-04-17 Nippon Shinyaku Co., Ltd. ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
CA3165961A1 (en) 2019-12-26 2021-07-01 Nippon Shinyaku Co., Ltd. Antisense nucleic acid that induces skipping of exon 50
AU2021226089A1 (en) 2020-02-28 2022-09-15 National Center Of Neurology And Psychiatry Antisense nucleic acid inducing skipping of exon 51
WO2022006871A1 (en) * 2020-07-10 2022-01-13 Changzhou Syntheall Pharmaceuticals Co., Ltd. Processes for preparing oligonucleotides
JP7825613B2 (ja) 2021-04-28 2026-03-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
US20240287511A1 (en) 2021-05-13 2024-08-29 National University Corporation Chiba University Antisense Oligomer
CN117500925A (zh) 2021-05-28 2024-02-02 住友制药株式会社 反义核酸
AU2022298028A1 (en) 2021-06-23 2023-12-21 National Center Of Neurology And Psychiatry Combination of antisense oligomers
JPWO2023282346A1 (enExample) 2021-07-08 2023-01-12
EP4368186A4 (en) 2021-07-08 2025-06-25 Nippon Shinyaku Co., Ltd. NEPHROTOXICITY REDUCING AGENT
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20250011777A1 (en) 2021-09-03 2025-01-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
JP2024537711A (ja) 2021-09-30 2024-10-16 サレプタ セラピューティクス， インコーポレイテッド １つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
KR20240129006A (ko) 2021-12-27 2024-08-27 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
IL315344A (en) * 2022-03-01 2024-10-01 Eisai R&D Man Co Ltd Bis-protected, activated guanine monomers
JP2025533454A (ja) 2022-09-21 2025-10-07 サレプタ セラピューティクス， インコーポレイテッド Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
TW202442246A (zh) 2023-04-27 2024-11-01 美商薩羅塔治療公司 用於治療慢性腎病之反義寡聚物
WO2025030099A1 (en) 2023-08-02 2025-02-06 Sarepta Therapeutics, Inc. Non-canonical cell-penetrating peptides for antisense oligomer delivery
AU2024362420A1 (en) 2023-10-18 2026-04-23 Murdoch University Antisense oligomers for treatment of centronuclear myopathies
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (enExample) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0962463B1 (en) * 1989-12-20 2002-07-10 Antivirals Inc. Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos

Similar Documents

Publication Publication Date Title
RU2010123958A (ru) Способ синтеза морфолиновых олигомеров
JP4675318B2 (ja) Ｎ−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるｎ−ヘテロアリール−ｎ−アリール−アミンの調製のためのプロセスおよび類似のプロセス
JP4642860B2 (ja) フルオロアルキルスルホンの光酸発生部が置換された新規の単量体およびその重合体
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EP3279181B1 (en) Method for producing a mixture of a polymerizable compound
JP2006517235A5 (enExample)
CN104520293A (zh) 抗病毒化合物的合成
JP2008528445A5 (enExample)
Aizpurua et al. “Click” synthesis of nonsymmetrical bis (1, 2, 3-triazoles)
BR122017005939B1 (pt) Processo para a fabricação de derivados de sulfamida pirimidina
Li et al. Rhodium (iii)-catalyzed aromatic C–H cyanation with dimethylmalononitrile as a cyanating agent
TW202216692A (zh) 新型Rho相關蛋白激酶抑制劑的製備方法和此製備方法中的中間體
CN116783160A (zh) 化合物库
JP2011527330A (ja) スニチニブリンゴ酸塩の結晶形の調製方法
TW201132630A (en) Imidazole derivatives
TWI225856B (en) Amide compounds
JP6112659B2 (ja) スルホニルアジド誘導体およびアシルスルホンアミド誘導体の製造方法並びにそれらの利用。
CN109963841A (zh) 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(5-巯基-1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈及制备方法
US8722916B2 (en) Cyclopropyl MIDA boronate
DK3044204T3 (en) PHOTOLABLE LINKS FOR PHASE PHYSICAL SYNTHESIS OF HYDRAZIDES AND PYRANOPYRAZOLES
CN113024470A (zh) 一种4-全氟烷基取代嘧啶化合物及其制备方法与应用
JP2023065526A (ja) 酸性官能基のアルキル化方法
JP2017504658A5 (enExample)
CN116903489A (zh) 三联苯类化合物、其制备方法及其应用
CN101190927B (zh) 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法